News

The FDA has announced a voluntary recall of several drug products containing the active ingredient valsartan, which is used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), a probable human carcinogen (a substance that could cause cancer), which was found in the recalled products.

The FDA has approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana.

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of naloxone hydrochloride injection at the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

The FDA has approved Aimovig (erenumab-aooe), a once-monthly, self-administered injection for the preventive treatment of migraine in adults. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.